A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
July 31, 2018
End Date
May 10, 2024
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
July 31, 2018
End Date
May 10, 2024